Keyphrases
Androgen Receptor
100%
Castration-resistant Prostate Cancer
100%
Ablative Therapy
100%
Bipolar Androgen Therapy
100%
Confidence Interval
55%
Enzalutamide
22%
Abiraterone
22%
Metastatic Cancer
22%
Patients with Cancer
22%
Hormonal Therapy
22%
Single Center
11%
Androgen Signaling
11%
Previously Treated
11%
Androgens
11%
Cohort Trial
11%
Testosterone
11%
Clinical Response
11%
Resistance Studies
11%
Multi-cohort
11%
Response Rate
11%
High-dose Testosterone
11%
Hormonal Treatment
11%
Trial Registration
11%
Luteinizing Hormone
11%
Disease Stabilization
11%
Co-agonist
11%
Overcoming Resistance
11%
Testosterone Administration
11%
Radiographic Progression-free Survival
11%
Testosterone Cypionate
11%
Intramuscularly
11%
Therapy Treatment
11%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen Receptor
100%
Castration Resistant Prostate Cancer
100%
Androgen
100%
Malignant Neoplasm
27%
Enzalutamide
18%
Hormone Cancer Therapy
18%
Abiraterone
18%
Progression Free Survival
9%
Gonadorelin Agonist
9%
Agonist-Antagonist
9%
Testosterone Cipionate
9%
Diseases
9%